The genetic variation of the tenomodulin gene (TNMD) is associated with serum levels of systemic immune mediators - The Finnish Diabetes Prevention Study

Genetics in Medicine

Volumn 10, Issue 7, 2008, Pages 536-544

  Tolppanen, Anna Maija ^a   Pulkkinen, Leena ^a   Herder, Christian ^b   Koenig, Wolfgang ^c   Kolehmainen, Marjukka ^a   Lindström, Jaana ^d   Tuomilehto, Jaakko ^d,e   Uusitupa, Matti ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Diabetes Unit

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cytokines; Inflammation; Molecular genetics; Obesity; Tenomodulin

Indexed keywords

ACUTE PHASE PROTEIN; AMYLOID A PROTEIN; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE MIGRATION INHIBITION FACTOR; MEMBRANE PROTEIN; PROTEIN TENOMODULIN; RANTES; UNCLASSIFIED DRUG; ISOMERASE; MIF PROTEIN, HUMAN; TNMD PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE METABOLISM; HAPLOTYPE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN MOTIF; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; FINLAND; GENE LINKAGE DISEQUILIBRIUM; GENETICS; GLUCOSE INTOLERANCE; MULTICENTER STUDY; STATISTICAL MODEL;

ACUTE-PHASE PROTEINS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; GENOTYPE; GLUCOSE INTOLERANCE; HAPLOTYPES; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LINKAGE DISEQUILIBRIUM; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MEMBRANE PROTEINS; MODELS, STATISTICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR5;

EID: 52049090836     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181772129     Document Type: Article

References (35)

1. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cydooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004;109:1729-1734.
2. Herder C, Peltonen M, Koenig W, et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the finnish diabetes prevention study. Diabetes 2006;55:2340-2346.
3. Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the cooperative health research in the region of augsburg survey S4 (KORA S4). Diabetes 2005;54(suppl 2):S11-S17.
4. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53:693-700.
5. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004;291:1978-1986.
6. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
7. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 1999;353:1649-1652.
8. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA augsburg cohort study, 1984-1998. Arch Intern Med 2003;163:93-99.
9. Tolppanen AM, Pulkkinen L, Kolehmainen M, et al. Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study. Obesity 2007;15:1082-1088.
10. Kolehmainen M, Salopuro T, Schwab US, et al. Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study. Int J Obes 2008;32:292-303.
11. Dahlman I, Under K, Arvidsson Nordstrom E, et al. Changes in adipose tissue gene expression with energy-restricted diets in obese women. Am J Clin Nutr 2005;81:1275-1285.
12. Tolppanen A-M, de Mello VDF, Lappalainen T, et al. Tenomodulin mRNA levels are correlated with serum and mRNA levels of inflammatory markers-the GENOBIN study [abstract]. Diab Vasc Dis Res 2007;4(suppl 1):19-20.
13. Brandau O, Meindl A, Fassler R, Aszodi A. A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I. Dev Dyn 2001;221:72-80.
14. Shukunami C, Oshima Y, Hiraki Y. Molecular cloning of tenomodulin, a novel chondromodulin-I related gene. Biochem Biophys Res Commun 2001;280:1323-1327.
15. Sanchez-Pulido L, Devos D, Valencia A. BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem Sci 2002;27:329-332.
16. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005;32:521-530.
17. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
18. Chen H. Cellular inflammatory responses: novel insights for obesity and insulin resistance. Pharmacol Res 2006;53:469-477.
19. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol 2006;54:375-386.
20. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292.
21. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
22. Eriksson J, Lindström J, Valle T, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the diabetes prevention study (DPS) in finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 1999;42:793-801.
23. Altshuler D, Brooks LD, Chakravarti A, et al. A haplotype map of the human genome. Nature 2005;437:1299-1320.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
25. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003;100:9440-9445.
26. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004;68(Pt 2):165-177.
27. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007;17:319-326.
28. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-966.
29. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003;27(suppl 3):S25-S28.
30. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004;92:347-355.
31. Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007;115:1029-1038.
32. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
33. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-7270.
34. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-1505.
35. Docheva D, Hunziker EB, Fassler R, Brandau O. Tenomodulin is necessary for tenocyte proliferation and tendon maturation. Mol Cell Biol 2005;25:699-705.